Vanda Pharmaceuticals, Inc. (VNDA)
-NasdaqGM 11.23 
0.32(2.77%) Jun 17, 4:00PM EDT
| Prev Close: | 11.55 |
|---|
| Open: | 11.50 |
|---|
| Bid: | 11.04 x 200 |
|---|
| Ask: | 12.25 x 300 |
|---|
| 1y Target Est: | 15.00 |
|---|
| Beta: | 1.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 11.09 - 11.97 |
|---|
| 52wk Range: | 2.92 - 13.30 |
|---|
| Volume: | 864,782 |
|---|
| Avg Vol (3m): | 728,734 |
|---|
| Market Cap: | 318.33M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.85 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Vanda says Phase III study data shows cortisol rhythm restorationtheflyonthewall.com(Mon, Jun 17)
- Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour DisorderPR Newswire(Mon, Jun 17)
- White Collar Criminals Love Biotech Stocksat Motley Fool(Sun, Jun 16)
- Assessing Raptor Pharmaceutical's Agreement With HealthCare Royalty Partnersat Motley Fool(Fri, Jun 14)
- What are hedge funds buying these days?at MarketWatch(Fri, Jun 14)
- 3 Stocks Near 52-Week Highs Worth Sellingat Motley Fool(Thu, Jun 13)
- 3 longs and 3 shorts to watchat MarketWatch(Wed, Jun 12)
- Put Options Active On AmerisourceBergenat Seeking Alpha(Tue, Jun 11)
- Vanda Pharmaceuticals: A Small-Cap Biotech With A Pipeline Allowing For Long-Term Growthat Seeking Alpha(Thu, Jun 6)
- Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour DisorderPR Newswire(Wed, Jun 5)
- Major confidence in Vanda PharmaoptionMONSTER(Wed, Jun 5)
- [video] Where to Invest Nowat CNBC(Tue, Jun 4)
- 4 Healthcare Stock Stories To Close Out the Weekat Wall St. Cheat Sheet(Fri, May 31)
- Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare ConferencePR Newswire(Fri, May 31)
- Traders selling puts as stocks churnoptionMONSTER(Fri, May 31)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 10.03 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.91 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -0.83 |
|---|
Business Summary
Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders.
View More